<ol class="cite-this-references"><li id="reference-A830">Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996 Apr 1;77(7):1356-62. [<a href="/articles/A830" target="_blank">Article</a>] </li><li id="reference-A831">Qweider M, Gilsbach JM, Rohde V: Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. J Neurosurg Spine. 2007 Mar;6(3):280-3. [<a href="/articles/A831" target="_blank">Article</a>] </li><li id="reference-A832">JOHNSON IS, ARMSTRONG JG, GORMAN M, BURNETT JP Jr: THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. Cancer Res. 1963 Sep;23:1390-427. [<a href="/articles/A832" target="_blank">Article</a>] </li><li id="reference-A833">Gidding CE, Kellie SJ, Kamps WA, de Graaf SS: Vincristine revisited. Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87. [<a href="/articles/A833" target="_blank">Article</a>] </li><li id="reference-L20449">FDA Approved Drug Products: Marqibo (vincristine sulfate liposome) for intravenous injection [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf" target="_blank">Link</a>] </li></ol>